Institutional and Insider Ownership
50.8% of Galera Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Acerus Pharmaceuticals and Galera Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acerus Pharmaceuticals | $2.12 million | 0.80 | -$33.82 million | ($3.57) | -0.06 |
| Galera Therapeutics | N/A | N/A | -$59.08 million | ($0.10) | -0.26 |
Risk & Volatility
Acerus Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Profitability
This table compares Acerus Pharmaceuticals and Galera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acerus Pharmaceuticals | -924.33% | N/A | -74.62% |
| Galera Therapeutics | N/A | N/A | -99.34% |
Summary
Galera Therapeutics beats Acerus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.
About Galera Therapeutics
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
